Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

PAC1 (IHC-grade), PACAP Receptor 1 Antibody

Citations
$ 375.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

  • 7TM0370N-IC
  • 100 µl
  • Rabbit
The PAC1 antibody is directed against the distal end of the carboxyl-terminal tail of human... more

The PAC1 antibody is directed against the distal end of the carboxyl-terminal tail of human PACAP Receptor 1. It can be used to detect total PAC1 receptors in Western blots independent of phosphorylation. The PAC1 antibody can also be used to isolate and enrich PAC1 receptors from cell and tissue lysates. It also detects PAC1 in cultured cells and tissue sections by immunohistochemistry.

  Alternative Names PAC1, PACAP Receptor 1, Pituitary Adenylate Cyclase... more

 

Alternative Names PAC1, PACAP Receptor 1, Pituitary Adenylate Cyclase Activating Polypeptide 1 Receptor
IUPHAR Target ID 370
UniProt ID  P41586
Western Blot (WB)  1:1000
Immunocytochemistry (ICC) 1:200
Immunohistochemistry (IHC) 1:100
Species Reactivity   Human
Host / Isotype Rabbit / IgG
Class Polyclonal
Immunogen A synthetic peptide presents distal end of carboxyl-terminal tail of human PAC1.
Form  Liquid
Purification Antigen affinity chromatography
Storage buffer Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions short-term 4°C, long-term -20°C
Figure 1. Immunohistochemical identification of PACAP Receptor 1 in human neuroendocrine... more

Figure 1. Immunohistochemical identification of PACAP Receptor 1 in human neuroendocrine tumor. Brain sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected at the plasma membrane of nearly all cells in neuroendocrine tumor.

Figure 2. Immunohistochemical identification of PACAP Receptor 1 in human enteric ganglia. Brain sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected in distinct population of cells in enteric ganglia.

Figure 3. Immunohistochemical identification of PACAP Receptor 1 in human cerebral cortex. Brain sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were predominately detected at the plasma membrane of pyramidal cells in cerebral cortex.

Figure 4. Immunohistochemical identification of PACAP Receptor 1 in human breast carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected at the plasma membrane of nearly all breast carcinoma cells.

Figure 5. Immunohistochemical identification of PACAP Receptor 1 in human ovarian carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, PAC1 receptors were uniformly detected at the plasma membrane of nearly all cells in ovarian carcinoma.

Figure 6. Validation of the PACAP Receptor 1 in transfected HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the human PACAP Receptor 1 (PAC1) were lysed and immunoblotted with the phosphorylation-independent anti-PAC1 antibody (7TM0370N-IC) at a dilution of 1:1000.

Figure 7. Immunocytochemical identification of PACAP Receptor 1 in HEK293 cells. HEK293 cells stably expressing the PACAP Receptor 1 (PAC1) were either not exposed or exposed to 1 μM PACAP (pituitary adenylate cyclase-activating peptide)) for 30 min and immunocytochemically stained with anti-PAC1 (PACAP Receptor 1) antibody (7TM0370N-IC) at a dilution of 1:200. Note, PAC1 receptors were confined to the plasma membrane in untreated cells (0 min). PAC1 receptors were seen in perinuclear clusters of vesicles after 30 min PACAP exposure.

Read, write and discuss reviews... more
Customer evaluation for "PAC1 (IHC-grade), PACAP Receptor 1 Antibody"
Write an evaluation
Evaluations will be activated after verification.

The fields marked with * are required.

Recently viewed